ClinicalTrials.gg
RecruitingNCT06728826PRINCE-CHUpdated Jul 14, 2026

Prevention of Atrial Fibrillation After Cardiac Surgery by Pericardiotomy

An interventional study of Posterior pericardiotomy in Atrial Fibrillation (AF), Cardiac Events and Pericardial Effusion, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

PRINCE-CH is a multicentre, randomized controlled trial which evaluates the effectiveness and safety of posterior pericardiotomy in preventing POAF after cardiac surgery in Chinese population.

Read the detailed description

Postoperative atrial fibrillation (POAF), defined as new-onset atrial fibrillation (AF) in the immediate period after surgery, is the most important type of secondary AF, which complicates 20-40% patients receiving cardiac surgery.

POAF is associated with haemodynamic instability , increased risk of stroke, lengthened hospital and intensive care unit stays and greater costs.

Pericardial effusion accumulated posterior to the left atrium after cardiac surgery could trigger atrial arrhythmias. Pericardiotomy allows for prolonged drainage of the pericardial effusion into left pleural space. Recent research evidence found that pericardiotomy was associated with a significantly lower incidence of POAF. The existing data on posterior pericardiotomy is promising for a reduction in POAF. The PRINCE trial's long-term follow-up of patients randomized to pericardiotomy could conclusively demonstrate whether the relationship of POAF to post-discharge clinical outcomes is causal and modifiable.

The PRINCE-CH trial will evaluate the effectiveness and safety of pericardiotomy in preventing POAF after cardiac surgery in Chinese population.

The intervention is posterior pericardiotomy and the control is no posterior pericardiotomy during cardiac surgery. The primary outcome is the occurrence of POAF.

The study will enrol 650 patients from 15 centres in China. All participants will be continuously monitored using a wearable body surface electrocardiogram (EKG) monitoring equipment from the day of surgery to 30 days after surgery.

02

Conditions studied

  • Atrial Fibrillation (AF)
  • Cardiac Events
  • Pericardial Effusion

Keywords

  • Pericardiotomy
  • Atrial Fibrillation
03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 650 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 355 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than or equal to 18 years of age
  • Requiring surgical intervention on proximal aorta, cardiac valves, and/or coronary arteries
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation or flutter
  • Reoperations/minimally invasive cardiac surgery/emergent presentation
  • Need for hypothermic circulatory arrest
  • Disease of the left pleura or previous left thoracotomy
  • Chest deformity
  • Unlikely to participate in follow-up assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Pericardiotomy Group

    The surgeon will perform posterior pericardiotomy during the cardiac surgery.

    Procedure: Posterior pericardiotomy

  • No intervention
    Control Group

    The surgeon will not perform posterior pericardiotomy during the cardiac surgery.

Interventions

  • ProcedurePosterior pericardiotomy

    The surgeon will perform a posterior pericardiotomy while the patient is on cardiopulmonary bypass. In detail, a 4-cm opening in the posterior pericardium will be made with a cautery between the left inferior pulmonary vein and the diaphragm. Then a soft channel drain will be placed through the opening in pericardium with the tip into the left pleural space.

06

What researchers measure

Primary outcomes

  1. Postoperative atrial fibrillation

    Number of patients with postoperative atrial fibrillation within the 30 days postoperatively

    Time frame: Within 30 days after index cardiac surgery

Secondary outcomes

  1. Atrial fibrillation burden

    The proportion of time spent in atrial fibrillation during the total time of cardiac rhythm monitoring within 30 days after the operation, expressed as a percentage.

    Time frame: Within 30 days after index cardiac surgery

  2. Heart rate variability

    Average HR(bpm), Highest HR(bpm), Lowest HR(bpm), pNN50(%), rMSSD(ms), SDNN(ms)

    Time frame: within 30 days of index surgery

  3. Antiarrhythmic drug use

    Number of patients received antiarrhythmic drug to control heart rhythm

    Time frame: within 30 days of index surgery

  4. Electrical cardioversion

    Number of patients received electrical cardioversion for severe heart arrhythmia

    Time frame: within 30 days of index surgery

  5. Length of stay in ICU

    Length of time in ICU

    Time frame: within 30 days of index surgery

  6. Duration of hospitalization

    Duration of hospitalization

    Time frame: within 30 days of index surgery

  7. Hospital readmission or unplanned hospital visit

    Number of hospital readmissions or unplanned hospital visits

    Time frame: within 30 days of index surgery

  8. Change in Quality of life

    Change in Quality of life assessed by the European quality of life index version 5D (EQ-5D-5L) questionnaire from baseline to 30 days after surgery

    Time frame: within 30 days of index surgery

Other outcomes

  1. Number of patients with cardiac tamponade

    Safety outcome

    Time frame: Within 30 days of index surgery

  2. Number of patients with left pleural interventions

    Safety outcome

    Time frame: Within 30 days of index surgery

  3. Number of patients with phrenic nerve injuries

    Safety outcome

    Time frame: Within 30 days of index surgery

  4. Number of patients requiring re-operation for bleeding

    Safety outcome

    Time frame: Within 48 hours of index surgery completion

  5. Ischemic stroke

    Safety outcome

    Time frame: within 30 days of index surgery

  6. Death

    Safety outcome

    Time frame: within 30 days of index surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06728826
Lead sponsor
Changhai Hospital
Collaborators
The General Hospital of Northern Theater Command
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Dec 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Hao Zhang, M.D. Ph.D.
Contact
13818178916@163.com
86-21-31161765
Lin Han, M.D. Ph.D.
study director · Naval Medical University Changhai Hospital
Huishan Wang, M.D. Ph.D.
study director · The General Hospital of Northern Theater Command
Hao Zhang, M.D. Ph.D.
principal investigator · Naval Medical University Changhai Hospital
Yuji Zhang, M.D. Ph.D.
principal investigator · The General Hospital of Northern Theater Command

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion